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Abstract
Background: In Major Depressive Disorder (MDD), treatment outcomes with currently available strategies are often
disappointing. Therefore, it is sensible to develop new strategies to increase remission rates in acutely depressed
patients. Many studies reported that true drug response can be observed within 14 days (early improvement) of
antidepressant treatment. The identical time course of symptom amelioration after early improvement in patients
treated with antidepressants of all classes or with placebo strongly suggests a common biological mechanism,
which is not specific for a particular antidepressant medication. However, the biology underlying early
improvement and final treatment response is not understood and there is no established biological marker as yet,
which can predict treatment response for the individual patient before initiation or during the course of
antidepressant treatment. Peripheral blood markers and executive functions are particularly promising candidates as
markers for the onset of action and thus the prediction of final treatment outcome in MDD.
Methods/Design: The present paper presents the rationales, objectives and methods of a multi-centre study
applying close-meshed repetitive measurements of peripheral blood and neuropsychological parameters in
patients with MDD and healthy controls during a study period of eight weeks for the identification of biomarkers
for the onset of antidepressants’ action in patients with MDD. Peripheral blood parameters and depression severity
are assessed in weekly intervals from baseline to week 8, executive performance in bi-weekly intervals. Patients are
participating in a randomized controlled multi-level clinical trial, healthy controls are matched according to mean
age, sex and general intelligence.
Discussion: This investigation will help to identify a biomarker or a set of biomarkers with decision-making quality
in the treatment of MDD in order to increase the currently disappointing remission rates of antidepressant
treatment.
Trial Registration: ClinicalTrials.gov: NCT00974155
Background
Major depressive disorder (MDD) is a severe psychiatric
disease that is characterized by depressed mood and loss
of interest or pleasure in daily activities, and is accom-
panied by weight change, sleep disturbance, fatigue,
physical impairment, diminished ability to think or con-
centrate and a high suicide rate. In Europe [1] and the
United States (US) [2], MDD belongs to the most preva-
lent mental disorders with lifetime and 12-months pre-
valence rates in the total population as high as 12.8%
(US: 16.2%) and 3.9% (US: 6.6%), respectively. Nearly all
patients with MDD suffer from mild to very severe
impairment in several domains of life like physical and
social activities, or occupational responsibilities [3].
MDD produces substantial costs through hospital
admissions, outpatient care and productivity loss as a
result of depression-related morbidity, suicide, and other
relevant parameters [4,5].
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The above mentioned data clearly indicate the utmost
importance of effective treatments for MDD. The use
of antidepressant drugs (ADs) for the treatment of
MDD is well established. However, effect sizes of cur-
rently available antidepressants are rather small than
medium [6-8] and treatment outcome remains disap-
pointing with remission rates of maximal 37% [[9] and
references inside]. Hence, it is sensible to develop
new strategies to increase remission rates in acutely
depressed patients.
Onset of antidepressants’ action
For decades, it has been common clinical view that
antidepressant response appears with a delay of several
weeks [10,11]. This hypothesis of a delayed action of
ADs had substantial impact on clinical practice. The
recommended treatment duration until insufficient
outcome can be assumed and treatment should be
optimised ranges between 3-4 weeks [12,13] and 4-8
weeks [14]. As marker for onset of action, a symptom
reduction of ≥ 50% at week 4 compared to treatment
initiation is generally accepted. Challenging the idea of
a delayed onset of ADs’ action, there is a substantial
body of evidence from many retrospective studies with
more than 33.000 patients treated with virtually all
groups of ADs strongly suggesting that a true drug
response can be observed within the first 10-14 days of
treatment [15-25]. The occurrence of improvement of
depressive symptoms in the early course of treatment
has been identified as being highly predictive for final
treatment outcome [15-18,22-25], corroborating the
idea that early improvement (typically defined as a 20%
reduction of depressive symptoms, measured with rat-
ing scales like the Hamilton Depression Rating Scale)
is an important clinical model for the onset of antide-
pressants’ action [26].
Biology underlying early improvement
Furthermore, it resulted in the idea that an effective
antidepressant treatment triggers and maintains condi-
tions necessary for recovery from the disorder. It has
been suggested that a biological, “resilience"-like compo-
nent is possessed that controls recovery from depression
to a major extent. Once triggered, recovery seems to fol-
low independent of pharmacologic differences of the
triggers. Consequently, the vast majority of patients
showing a favourable later outcome experience the
respective onset within the first 2 weeks of treatment.
Inversely, non-improvement after 2 weeks of treatment
seems to indicate that a selected AD did not trigger the
resilience-like component and has strongly limited
chances to do so, even if continued in the course of
treatment [22].
Biomarkers could establish the basis for individualised
treatment approaches
The virtually identical time course of symptom ameli-
oration after early improvement in patients treated with
antidepressants of all classes or with placebo strongly
suggests that early improvement and the successive time
course of response reflect a common biological mechan-
ism, which is not specific for a particular antidepressant
medication. However, the neurobiological substrates of
this remarkably robust relation between early improve-
ment and final treatment outcome need to be elucidated.
The lack of this knowledge also means that there is cur-
rently no validated biomarker for the onset of antide-
pressants’ action and final treatment response during
the course or before the initiation of an antidepressant
treatment. The identification of biomarkers could lead
to the development of effective personalized antidepres-
sant treatment. Biomarkers may give an insight into the
underlying biological basis of depression, which can be
used to develop more effective drug treatments and
therefore shorten the time to response or remission.
The term ‘biomarker’ is used here to describe a biologi-
cal change associated with depression that could be
used to indicate the presence and severity of the condi-
tion and predict drug or other treatments’ response as
well as the clinical prognosis [27]. The idea behind iden-
tifying biomarkers is that they will allow the identifica-
tion of patients that benefit from antidepressants that
specifically target a patient’s individual psychopathology
[28]. The present scientific investigation should help to
close this significant gap of current research and lead to
the identification of biomarkers that increase the risk
for depression and mirror the antidepressant treatment
response. Thereby, these analyses should establish the
basis for individualised treatment approaches, leading to
better treatment outcomes with less adverse effects and
in a shorter period of time.
Peripheral blood markers could serve as biomarkers for
antidepressant treatment response
Although the search for peripheral blood markers for
psychiatric disorders lasts for many years, a non-invasive
blood-based test that could be used for diagnosis, help
to stratify patients based on disease subtypes or indicat-
ing the onset of antidepressants’ action has not been
identified as yet. Several neurotrophic factors comprising
brain- and glia-derived neurotrophic factors as well as
cytokines and insulin-like growth factor 1 are discussed
as potential blood markers [27]. For depression, monoa-
mine-related markers have been studied with only par-
tial success in terms of specificity of the marker, or
replication of the findings. More recently, a number of
studies have been carried out to evaluate the potential
of neurotrophic markers such as the brain derived
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eases, again resulting in evidence of association but also
with many non specific or conflicting findings. The find-
ing of an HPA dysfunction in depressed patients during
acute phase has led to the development of neuro-endo-
crine challenge tests as putative biomarkers. Another
interesting line of research has focused on inflamma-
tory-related markers, based on the evidence of reciprocal
communication between immune and nervous systems
and of altered immunological state in psychiatric dis-
eases. For depression in particular a ‘’cytokine hypoth-
esis’’ has been developed that associates the
dysregulation of the immuno-inflammatory system with
the aetiology and the pathophysiology of MDD.
Recently, a larger panel of pro- and anti-inflammatory
cytokines was measured in a case/control population of
MDD showing elevation of a number of additional cyto-
kines not previously implicated in MDD, as well as of
some previously untested chemokines [29].
In the context of personalized medicine, it might be
straightforward to identify valid biomarkers based on
protein analysis, because most drugs act on proteins.
However, such biomarkers remain to be discovered; the
human body is believed to contain more than a million
different proteins and their expression fluctuates con-
stantly [28]. Another reason reason for the failure of
previous studies on biomarkers for the onset of antide-
pressants’ action might be that they were usually
restricted to either one measurement (baseline) or two
measurements with an interval of at least 4 weeks (e.g.
before and after antidepressant treatment), reflecting the
traditional view of a delayed onset of antidepressants’
action. Taking into account the above mentioned studies
showing that true drug response can be observed within
the first 10-14 days of antidepressant treatment, it might
be more appropriate and promising to focus on biomar-
kers’ reactions in the first 7-14 days after initiation of
antidepressant treatment.
Executive functions could serve as markers for
antidepressant treatment outcome
A further approach to identify markers of treatment
response in Major Depressive Disorder (MDD) is the
investigation of neuropsychological functions. In patients
with MDD, empirical evidence supports the existence of
moderate but significant neuropsychological deficits
[30,31]. With respect to cognitive domains, impairment
has been reported for executive functioning in particular
[32], whereas less significant deficits have been found for
psychomotor speed [33], attention [34] and memory [35].
Deficits seem to increase with the number of depressive
episodes, melancholic symptoms and age [36,37].
Many studies reported a substantial improvement in neu-
ropsychological functioning during the course of an
antidepressant treatment in patients with MDD
[30,37-39]. Nevertheless, the results of these studies are
heterogeneous and support the hypothesis that some
cognitive deficits, like executive dysfunctions, improve
during the course of an antidepressant treatment whereas
other impairments, specifically memory impairments,
often persist after the remission of the depressive symp-
toms [40,41]. Multiple studies reported an association
between the time course of symptom amelioration of
MDD and the performance in word fluency, cognitive
flexibility and working memory tasks [31,38,39,42-45].
Furthermore, studies show that non-responders to an
antidepressant treatment have a poorer pre-treatment
performance in cognitive functions than responders [46].
Recent studies demonstrated the involvement of a
consistent set of limbic and cortical regions in both uni-
polar and bipolar depression as well as replicable pat-
terns of activation changes with various antidepressant
treatments [47,48]. Furthermore, a fluoxetine study in
patients with MDD revealed sub-cortical metabolic
changes, which were already seen after 1 week of antide-
pressant treatment, although patients showed no change
in depressive symptoms. The reversal of this week-1 pat-
tern at 6 weeks was seen uniquely in those patients
showing a clinical response. These results suggest a
requisite process of neural adaptation in specific brain
regions during antidepressant treatment [47,48].
Objectives
The present paper presents the rationales, objectives and
methods of two complementing clinical studies [addi-
tional scientific investigations to the “Randomised clinical
trial comparing early medication change (EMC) strategy
with treatment as usual (TAU) in patients with Major
Depressive Disorder - the EMC trial” and “the EMC Con-
trol study"] applying repetitive measurements of periph-
eral blood and neuropsychological parameters in patients
with MDD and healthy controls during a period of eight
weeks in order to identify biomarkers for the onset of
antidepressants’ action in patients with MDD.
Previous studies suggest that peripheral blood and
neuropsychological parameters might be useful in the
prediction of treatment response before and after initia-
tion of an antidepressant treatment and thus might be
useful for the selection of a particular antidepressant
medication. Therefore, the present study has two main
objectives:
I. Association between early changes of peripheral
blood parameter/neuropsychological functioning with
final treatment outcome:
▪ Changes of peripheral blood parameters/neuropsy-
chological functioning in the early course of treat-
ment (baseline [BL] - day 7/14) account for a high
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depression severity (HAMD-17).
▪ Changes of peripheral blood parameters/neuropsy-
chological functioning in the early course of treat-
ment (baseline [BL] - day 7/14) predict later
treatment response and remission with high sensitiv-
ity and specificity.
II. Association between a concurrent occurrence of
early changes of peripheral blood parameters/neuropsy-
chological function and early improvement with final
treatment outcome:
▪ Concurrent changes of peripheral blood para-
meters/neuropsychological functioning plus early
improvement account for a higher percentage of var-
iance of final changes in depression severity than
early changes of peripheral blood markers or early
improvement alone.
▪ Concurrent changes of peripheral blood para-
meters/neuropsychological functioning plus early
improvement predicted later treatment response or
remission with higher sensitivity and specificity than
early changes of peripheral blood parameters or
early improvement alone.
Methods/Design
Participants
Patients
In line with the above mentioned rationales and objec-
tives, the herein presented study in patients was
designed as a scientific investigation additional to the
“Randomised clinical trial comparing an early medica-
tion change (EMC) strategy with treatment as usual
(TAU) in patients with Major Depressive Disorders
(MDD) - The EMC Trial (ClinicalTrials.gov identifier n°:
NCT00974155)”. The detailed study protocol of The
EMC Trial has been reported previously [49]. In brief,
The EMC Trial is a phase IV, multi-centre, multi-step,
randomized, observer-blinded, actively controlled paral-
lel-group clinical trial to investigate for the first time
prospectively, whether non-improvers after 14 days of
antidepressant treatment with an early medication
change (EMC) are more likely to attain remission
(HAMD-17 ≤ 7) on treatment day 56 compared to
patients treated according to current guideline recom-
mendation (treatment as usual; TAU). In level 1 of the
EMC trial, non-improvers after 14 days of antidepres-
sant treatment will be randomised to an EMC strategy
or TAU. The EMC strategy for this study schedules a
first medication change on day 15; in case of non-
improvement between days 15-28, a second medication
change will be performed. TAU schedules the first
medication change after 28 days in case of non-response
(HAMD-17 decrease <50%). Both interventions will last
42 days. In levels 2 and 3, EMC strategies will be com-
pared with TAU strategies in improvers on day 14, who
experience a stagnation of improvement during the
course of treatment. The trial is supported by the Ger-
man Federal Ministry of Education and Research
(BMBF) and is conducted in cooperation with the
BMBF funded Interdisciplinary Centre for Clinical Trials
(IZKS) at the University Medical Centre Mainz and at
six clinical trial sites in Germany.
In order to acquire a sample representative of inpatients
with MDD, the study has broad inclusion criteria that
allow enrolment of both adult and elderly patients, moder-
ately to very severely depressed patients as well as MDD
patients with psychiatric comorbid disorders. The detailed
in- and exclusion criteria have been previously reported
[49]. Key inclusion criteria are [1] Major Depressive Disor-
der (MDD), first episode or recurrent, according to DSM-
IV; [2] a HAMD17 score of ≥18 pts.; [3] age 18 - 65 years
and ≤60 years at the time of the first depressive episode.
Key exclusion criteria are [1] acute risk of suicide needing
an intervention not comprised by protocol treatment (e.g.
electroconvulsive therapy); [2] lifetime DSM-IV diagnosis
of dementia, schizophrenia, schizoaffective disorder, bipo-
lar disorder; [3] current DSM-IV diagnosis of posttrau-
matic stress disorder, obsessive-compulsive disorder,
anxiety disorder, or eating disorder and the requirement
of a treatment not comprised by protocol treatment; [4]
DSM-IV substance dependency requiring acute detoxifica-
tion; [5] depression due to organic brain disorder, e.g.
Multiple Sclerosis and Parkinson’sD i s e a s e ;[ 6 ]w o m e n
who are pregnant, breastfeeding or planning to become
pregnant during the trial.
Healthy volunteers
In order to assure the specificity of the study results, the
results of MDD patients will be compared to those of
healthy controls. Seventy-five healthy controls will be
included in the study. Patients and healthy controls will
be matched by age, gender and general intelligence. The
inclusion criteria are: [1] mentally healthy, confirmed by
the M.I.NI. International Neuropsychiatric Interview and
the Structured Clinical Interview for DSM-IV Axis II
Personality Disorders (SCID-II); [2] ability of subjects to
understand character and individual consequences of
clinical trial; [3] signed and dated informed consent of
the subject must be available before start of any specific
trial procedures. The exclusion criteria are: [1] current
medication; [2] missing German language ability; [3]
cognitive impairment which interferes with subjects’
ability to participate in the psychopathological interviews
or neuropsychological testing; [4] a history of cranio-
cerebral injury; [5] relevant organic disease, e.g. Multiple
Sclerosis or Morbus Parkinson.
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Table 1 shows the study procedures for patients and
healthy controls.
Assessment of mental disorders
Diagnosis as well as possible comorbid psychiatric dis-
eases will be assessed at screening (EMC Trial) or at
baseline (controls).
￿ DIA-X-SSQ [50]: For the pre-screening of DSM-IV
axis I disorders in healthy controls, the screening
questionnaire of the DIA-X-Interview will be
applied.
￿ M.I.N.I. International Neuropsychiatric Interview
[51]: The M.I.N.I is a structured clinical interview to
assess mental disorders according to DSM-IV [52]
and ICD-19 [53].
￿ Structured Clinical Interview for DSM-IV Axis II
Personality Disorders (Scid-II) [54]: The SCID is a
structured clinical interview to diagnose personality
disorders.
Assessment of depression severity
￿ Hamilton Depression Rating Scale (HAMD17) [55]:
Depression severity will be assessed using the 17-
item version of the Hamilton-Depression-Rating-
Scale (HAMD17). Each item refers to a different
depressive symptom; the severity of each symptom
will be expressed with a score ranging from 0-2, 0-3,
or 0-4.
￿ Inventory of Depressive Symptoms (IDS-C30/-SR30)
[56]: Additionally, depression severity will be
assessed with the 30-items clinician-rated and self-
rated version of the Inventory of Depressive Sympto-
matology (IDS-C30 and IDS-SR30, resp.). Each item
refers to a different depressive symptom; the severity
of each symptom will be expressed with a score ran-
ging from 0-3.
Assessment of function
￿ Short-Form Health Survey (SF-12) [57]: The SF-12
is a measure for health-related quality of life inde-
pendent of psychiatric diagnosis. Its 12-item version
Table 1 Trial schedule of patients and healthy controls
Visit (V)/Action SC BL V1 V2 V3 V4 V5 V6 V7 V8
Trial day -14-0 0 7 ± 2 14 ± 2 21 ± 2 28 ± 2 35 ± 2 42 ± 2 49 ± 2 56 ± 2
Prescreening
DIA-X-SSQ
1) X
Basic documentation
Inclusion/exclusion criteria X
Patient information and consent X
Demographics X
Medical history X
Diagnostic procedures
M.I.N.I. SCID-II X
2) XX
3) X
Treatment outcome
HAMD-17 IDS-C30 IDS-SR30 SF-12 X X X X X X X X X
Peripheral blood
Serum X X X X X X X X X
Plasma X X X X X X X X X
Whole blood (EDTA) X X X X X X X X X
Neuropsychology
MWT X
R W T X XXXX
T M T A / B X XXXX
RWT (category change) X X X
DOT X X X
RFFT X X X
End of trial X
1) only in healthy controls; 2) in patients at screening visit; 3) in healthy controls at baseline visit; SC = Screening; BL = Baseline; V1 = Visit 1, V2 = Visit 2, V3 =
Visit 3, V4 = Visit 4, V5 = Visit 5, V6 = Visit 6, V7 = Visit 7, V8 = Visit 8; DIA-X-SSQ = Screening Questionnaire of the DIA-X-Interview, M.I.N.I. = MINI International
Neuropsychiatric Interview; SCID-II = Structured Clinical Interview for DSM-IV Axis II Personality Disorders; HAMD17 = Hamilton Depression Rating Scale; IDS-C30 =
Inventory of Depressive Symptoms - Interview, IDS-SR30 = Inventory of Depressive Symptoms - Self rating, MWT = Multiple Vocabulary Test, TMT = Trail Making
Test, DOT = Adaptive Digit Ordering Test, RFFT = Ruff Figural Fluency Test.
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“psychic health” as subscales. Each item refers to a
different symptom concerning “physical health” and
“psychic health"; the severity of each symptom will
be expressed with a score ranging from 1-2, 1-3, 1-5,
or 1-6.
Biomaterial
￿ Serum/plasma: For the purpose of identification of
serum and plasma markers of depression and antide-
pressant treatment response, serum and plasma pro-
teins, which are possibly suitable to discriminate
between depressive patients and healthy controls or
to predict treatment response in major depression,
will be analyzed in parallel to clinical assessments, i.
e. from baseline to day 56 in weekly intervals. Serum
and plasma will be extracted from whole blood
using standard laboratory procedures and deep fro-
zen (-80°C) until analysis. Date and time of blood
withdrawal, time of start and stop of centrifugation
as well as time of placement in the freezer will be
recorded in the electronic case record form (eCRF).
￿ Molecular genetic markers: For the purpose of
identification of molecular genetic markers of
depression and antidepressant treatment response,
molecular genetic markers (DNA variations, epige-
netic structures, RNA expression), which are possi-
bly suitable to discriminate between depressive
patients and healthy controls or to predict treatment
response in major depression will be analyzed. For
these analyses, whole blood (EDTA) samples at the
baseline visit and at each following visit (V1-8) are
necessary. Whole blood will be deep frozen until
analysis. Date and time of blood withdrawal as well
as the time of placement in the freezer (-80°C) will
be recorded in the eCRF.
Neuropsychological tests
￿ Multiple Vocabulary Test (MVT) [58]: Premorbid
intelligence is examined using a test for crystallized
intelligence. Patients have to differentiate real Ger-
man words from pseudowords. Results are reported
as the raw score of the correct words. The MVT will
be applied at baseline.
￿ Verbal fluency Test (RWT) [59]: Verbal fluency is
assessed by the Regensburger Verbal Fluency Test
(RWT). The RWT is composed of lexical and
semantic fluency tasks. In the subtest “Verbal Letter
Fluency”, participants will be instructed to generate
as many words beginning with a specific letter as
they could think of in 2 minutes. In the semantic
fluency task, subjects will be instructed to generate
as many words (e.g. dog) as possibly being part of a
specific category (e.g. animals) in 2 minutes. The
measure of performance is the number of correct
words given in 2 minutes. The RWT consists of five
alternate forms. Each of the alternate forms will be
applied once at baseline and then in bi-weekly inter-
vals (visits 2, 4, 6, and 8). The five alternate versions
were randomly distributed to the visits.
￿ Trail Making Test (TMT) [60]: The TMT is a fre-
quently used measure of executive cognitive func-
tions. The TMT-A assesses processing speed, the
TMT-B cognitive flexibility und task swifting. Both
parts of the Trail Making Test consist of 25 circles
distributed over a sheet of paper. In part A, the cir-
cles are numbered 1-25, and the patient should draw
lines to connect the numbers in ascending order. In
part B, the circles include both numbers (1-13) and
letters (A-L); as in part A, the patient draws lines to
connect the circles in an ascending pattern, but with
the added task of alternating between the numbers
and letters (i.e., 1-A-2-B-3-C, etc.). In a previous
study we developed and validated three alternate
forms of the TMT A and B (Wagner et al., in pre-
peration). Thus, the TMT consists of four alternate
forms, which were randomly distributed to the visits.
￿ Adaptive Digit Ordering Test (DOT) [61]: Working
memory is assessed by the DOT. The DOT consists
of six items of increasing length (three to eight
digits). Each item comprises of two trials. Subjects
are asked to repeat these digits in accenting order
immediately after presentation. The DOT consists of
two alternate forms. One alternate version will be
applied at baseline and visit 8, the other version in
visit 2. The versions were randomly distributed to
the subjects.
￿ Ruff Figural Fluency Test (RFFT) [62]: The RFFT
was developed to provide clinical information
regarding nonverbal capacity for fluid and divergent
thinking, ability to flexibly shift cognitive set, plan-
ning strategies, and executive ability to coordinate
this process. The RFFT was designed as a nonverbal
analogue to popular verbal fluency tests. The Test
Booklet consists of five 60-second parts, each with a
different stimulus presentation. The task is to draw
as many unique designs as possible within a set per-
iod of time (60 seconds) by connecting the dots in
different patterns. The RFFT is applied at baseline as
well as in visite 2 and 8. It consists of five alternate
forms. We use the alternate forms 1, 4 and 5 in this
study, because version 4 and 5 are variations of the
original version 1. The three versions were randomly
distributed to the visits.
Sample size
T h es a m p l es i z ec a l c u l a t i o ni sb a s e do nt h el a r g eb o d y
of evidence showing a different treatment outcome in
patients with or without early improvement as well as
on the assumption of a close relationship between early
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the sample size calculation we assume that patients with
early improvement display specific changes of biomar-
kers and that treatment response will be higher in sub-
jects with biomarker changes (group 1) than in patients
without biomarker changes (group 2). Differences
between the frequency of patients with and without
these changes will be calculated by a Chi
2-Test. Signifi-
cance will be set at p ≤ 0.05. Based on treatment
response rates of patients with or without early
improvement we expect a treatment response rate of 0.5
in group 1 and of 0.2 in group 2. These proportions
result in an odds ratio of 0.250. Expecting a sample size
ratio between group 1 and 2 of 0.54, a required sample
sizes of 128 patients per group (alpha = 0.05, Fisher’s
exact test, 2-sided) for a power of 80% will be needed.
For the replication sample, the same sample size is
assumed (=> 256 patients). If 12% of patients are drop-
outs, a total sample size of N = 287 patients will be
needed.
Four of the six trial sites of the EMC Trial are
involved in the collection of blood; at these trial sites,
approximately 450 patients will be included during the
study period. Neuropsychological functioning will be
assessed at two trial sites of the EMC trial; at these trial
sites, approximately 290 patients will be investigated.
Therefore, the recruited number of patients will be suffi-
cient for the testing of the above mentioned hypotheses
including replication samples.
Differences between patients and healthy controls
will be calculated by t-tests for independent variables
(alpha = 0.05, 2-sided). For a power of 90% and an effect
size of .80 a sample size of 50 healthy controls will be
needed. Due to a lower motivation of the healthy con-
trols to participate in the study during the whole study
period, a drop out rate of 25% in healthy control is
assumed. Therefore, it is planned to assess 70 healthy
controls.
Staff training
For the collection of biomaterial, standard operating
procedures (SOP) have been developed and thoroughly
tested at the Department of Psychiatry and Psychother-
apy at the University Medical Center Mainz (UMCM).
At each trial site, study nurses were trained in the appli-
cation of SOPs by staff members of the Dept. of Psy-
chiatry and Psychotherapy, UMCM. Study nurses of trial
sites are supervised in monthly intervals.
For the assessment of depression severity, 17 psychol-
ogists and four residents in psychiatry were trained
(HAMD-17; IDS). The training was carried out using
five video tapes of patients with DSM-IV Major Depres-
sion [63]. The training revealed that accuracy and inter-
rater reliability of the HAMD17 and IDSC30 were already
high in the first rating and increased during the course
of the training [64]. The training sessions were orga-
nized in a standardized manner. After an introduction
section on the theoretic background and use of HAMD
and IDS, five HAMD17 and three IDS30CR videos were
shown. After each video, individual ratings were carried
out following a discussion of the results.
Psychologists of the in the participating trial sites were
trained in the application of the neuropsychological
tests. At the beginning, all raters had to execute the test
by themselves. After that, there was an introduction in
theoretic background and test procedures of the neurop-
sychological tests. Last, all raters had to execute the
tests under supervision of an expert in neuropsychologi-
cal testing (SW).
Ethical issues
The procedures set out in this trial protocol, pertaining
to the conduct, evaluation, and documentation of this
trial, are designed to ensure that all persons involved in
the trial abide by good clinical practice (GCP) and the
ethical principles described in the Declaration of Hel-
sinki. The trial will be carried out in accordance with
local legal and regulatory requirements. The require-
ments of the AMG, the GCP regulation, and the Federal
Data Protection Law (BDSG) will be kept. Before being
admitted to the clinical trial, the subject must consent
to participate after being fully informed about the nat-
ure, scope, and possible consequences of the clinical
trial. After reading the informed consent document, the
subject must give consent in writing. The subject’sc o n -
sent must be confirmed by the personally dated signa-
ture of the subject and by the personally dated signature
of the person conducting the informed consent discus-
sions. All study components were approved by the local
ethics committee of the Landesärztekammer Rheinland-
Pfalz (study code n°: 837.211.09/6717 (patients), n°:
837.476.09/6982 (healthy controls)) and is compliant
with the Code of Ethics of the World Medical Associa-
tion (Declaration of Helsinki).
Discussion
The traditional idea of a delayed onset of antidepressants’
action was fundamental for the design of previous studies
searching for biomarkers indicating the onset of antide-
pressants’ action. As a consequence of the delayed-onset
hypothesis, previous studies in the field mainly focused
on treatment outcomes after several weeks or even
months of antidepressant treatment. This approach
might be related to the fact that there are no established
biomarkers for the onset of antidepressants’ action as yet
and treatment efficacy is only determined by clinical
measures and in the later course of treatment. Currently
available data can not answer the question, whether the
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meters during the course of treatment might be useful
biomarkers in clinical practice or in the research of new
antidepressant substances, because studies so far were
typically restricted to two measurements, one before and
one after antidepressant treatment. In order to evaluate
the potential clinical value of measuring biomarker
changes, it is essential to evaluate the significance of early
changes of biomarkers for the finally achieved changes of
these markers and, even more important, depression
severity. For the investigation of the predictive value of
early changes of biomarkers for final treatment outcome,
repetitive measures in weekly intervals are necessary to
demonstrate the detailed time course of biomarkers as
well as depression severity. The present study is a scienti-
fic investigation conducting close-meshed repetitive mea-
surements of peripheral blood and neuropsychological
markers for the onset of antidepressants’ action and final
treatment response in patients with MDD (DSM-IV) dur-
ing a period of eight weeks. The assessment of peripheral
blood and executive parameters in patients participating
in this study should extent the existing knowledge about
their predictive value for antidepressant treatment
response. These analyses should further broaden the
basis for individualised treatment approaches, leading to
better treatment outcomes with less adverse effects and
in a shorter period of time. The present study is unique
because it will enable for the first time the determination
o fac l o s e - m e s h e dt i m ec o u r s eo fm a n yp e r i p h e r a lb l o o d
and neuropsychological parameters in parallel to depres-
sion severity, taking into account the large data base
showing that the onset of antidepressants’ action takes
place in the first 10-14 days after treatment initiation.
Parallel to this close-meshed collection of biomaterial,
detailed blinded assessments of psychopathology by
trained raters establish the phenotype “treatment out-
come in MD”. The aim of this study is to investigate the
relationship between ii) early changes of peripheral blood
markers/neuropsychological performance and final
changes of depression severity during short-term antide-
pressant treatment in patients with MDD; and ii) a con-
current occurrence of early changes of peripheral blood
parameters/neuropsychological functioning plus early
improvement with the final treatment outcome. With
this multi-level investigation we hope to provide data
helping to establish a biomarker or a set of biomarkers
with decision-making quality in the treatment of MDD in
order to increase the currently disappointing remission
rates of antidepressant treatmen t .F o rt h i sg o a l ,e x t e r n a l
researchers may collaborate and request access to the
material or data.
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